PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of scirepAboutEditorial BoardFor AuthorsScientific Reports
 
Sci Rep. 2017; 7: 7029.
Published online 2017 August 1. doi:  10.1038/s41598-017-07356-9
PMCID: PMC5539300

Suppression of Transposable Elements in Leukemic Stem Cells

Abstract

Genomic transposable elements (TEs) comprise nearly half of the human genome. The expression of TEs is considered potentially hazardous, as it can lead to insertional mutagenesis and genomic instability. However, recent studies have revealed that TEs are involved in immune-mediated cell clearance. Hypomethylating agents can increase the expression of TEs in cancer cells, inducing ‘viral mimicry’, causing interferon signalling and cancer cell killing. To investigate the role of TEs in the pathogenesis of acute myeloid leukaemia (AML), we studied TE expression in several cell fractions of AML while tracking its development (pre-leukemic haematopoietic stem cells, leukemic stem cells [LSCs], and leukemic blasts). LSCs, which are resistant to chemotherapy and serve as reservoirs for relapse, showed significant suppression of TEs and interferon pathways. Similarly, high-risk cases of myelodysplastic syndrome (MDS) showed far greater suppression of TEs than low-risk cases. We propose TE suppression as a mechanism for immune escape in AML and MDS. Repression of TEs co-occurred with the upregulation of several genes known to modulate TE expression, such as RNA helicases and autophagy genes. Thus, we have identified potential pathways that can be targeted to activate cancer immunogenicity via TEs in AML and MDS.

Introduction

Transposable elements (TEs) have been mostly considered detrimental because of their inherent mobile nature. Their expression can lead to insertional mutagenesis, chromosomal rearrangements, and genomic instability, potentially contributing to cancer development14. TEs have the ability to transpose to new sites through a cut-and-paste mechanism (DNA transposons) or through RNA intermediates by a copy-and-paste mechanism (retrotransposons). Retrotransposons are further classified into long terminal repeat (LTR) and non-LTR elements. Endogenous retroviruses (ERV), which are LTRs, resemble retroviruses in their structure and function. Long interspersed nuclear elements (LINE) such as LINE1 are non-LTRs, and autonomous in their ability to retrotranspose, whereas short interspersed nuclear elements (SINE) such as Alu are non-autonomous, and dependent on LINE for retrotransposition. TEs are highly expressed during embryogenesis and play an active role in it5, 6. TEs have also been suggested to have played a positive role in evolution by increasing the potential for advantageous novel genes710.

The genomic regions that contain TEs are highly methylated and are silenced by heterochromatin in the somatic cells11, 12. TE activation has been reported in aging tissues, including in aging stem cells13, 14. TEs have been reported to be expressed in various types of cancers for the past 3 decades; however, it remains unknown if they are causal or consequential to the development of cancer. Recent reports revealed a potential beneficial role of TEs in cancer, wherein ERVs were shown to be potential tumour-specific antigens15. Hypomethylating agents increase the expression of TEs in cancer cells, inducing ‘viral mimicry’ and causing interferon signalling and cancer cell killing16, 17. Bidirectional (sense and anti-sense) transcription of many TEs, including ERVs, yields dsRNA18, 19. dsRNA sensors then activate potent interferon response pathways, leading to the activation of inflammatory pathways and cell death16, 17. These findings suggested that TE expression in cancer cells could play a role in immune-mediated clearance of cancer cells.

Acute myeloid leukaemia (AML), the most common form of acute leukaemia in adults, is characterized by high rates of initial remission with chemotherapy (60–70%), but is also associated with high relapse rates. Nearly two decades ago, it was shown that only a small fraction of AML cells (termed leukemic stem cells or LSCs) were capable of re-initiating the tumour when transplanted into immunodeficient animals20. LSCs in AML can be identified based on the expression of cell surface proteins (CD34+CD38negCD99+TIM3+)21. Although the exact role of LSCs in the pathogenesis and relapse of AML is still debated, their presence is associated with resistance to therapy, relapse, and poor prognosis22. Thus targeting LSCs in AML is a major focus of oncologic research, however the lack of understanding of pathways dysregulated in LSCs has hampered progress. We speculated that the resilience of LSCs was mediated by its ability to escape immune mediated clearance. To investigate this, we studied the expression of TEs and its accompanying immune pathways in AML cell fractions.

Materials and Methods

See supplemental section for materials and methods.

Results

LSCs show low expression of TEs

Corces et al. had recently used fluorescent activated cell sorting to isolate leukemic cells from patients with AML. They separated the cells of three distinct stages of AML evolution, pre-leukemic haematopoietic stem cells (pHSCs; CD34+CD38negCD99negTIM3neg), leukemic stem cell (LSCs; CD34+CD38negCD99+TIM3+), and leukemic blasts (Blasts; CD99+TIM3+CD45midSSChigh), characterized their transcriptome, and analysed their coding gene expression patterns21. To investigate the regulation of TEs in the development of AML, we examined the transcriptomes in these stages by measuring the changes in TE expression. When LSCs were compared to pHSCs and Blasts, we identified a significant downregulation of TEs in LSCs (Fig. 1a,b, and Supplement Fig. 1). Among the different classes of TEs, SINE was the most suppressed in LSCs, followed by LTR retrotransposons (Fig. 1a). The most dysregulated TE types in LSCs were Alu, ERV1, ERVL, ERVK, and LTR retrotransposons, all of which showed significant suppression (Supplement table 1).

Figure 1
Analysis of differential expression of transposable elements in pre-leukemic stem cells (pHSC), leukemic stem cells (LSC), and Blasts (a) X-axis; Patient identifier. The expression levels in log10 using the metric transcripts per million (TPM). The ‘Transposable ...

We further analysed the dysregulation of TEs in individual AML samples, while tracking the stages of AML. We found that specific TE types were dysregulated, with LSCs showing significant suppression of Alu, ERV3. ERVK, ERVL, and LTR retrotransposons (Fig. 1c, Supplement Fig. 2). We did not observe significant suppression of LINE1 in LSCs. These results suggested that TEs were dysregulated during AML development, with LSCs showing significant suppression of specific TE types.

LSCs show suppression of interferon pathways

LSCs are known to be resistant to treatment and serve as potential sources of relapse for AML, although the mechanisms behind this resilience are not fully understood22. Expression of TEs is known to activate a viral recognition pathway, which causes interferon signalling and immune-mediated cell clearance16, 17. Because LSCs showed suppressed TE expression, we investigated whether this TE suppression was associated with the suppression of interferon pathways in LSCs, which could enable its escape from immune-mediated clearance. LSCs showed significantly higher suppression of several Gene Ontology Consortium (GO)-interferon signalling pathways than Blasts (Fig. 2a). When immune-related pathways (with a set of 335 genes, generated by combining 17 canonical immune pathways in MSigDB) and inflammatory pathways (with a set of 649 genes combining acute inflammatory response and inflammatory response in MSigDB and GO) in LSCs and Blasts were compared, LSCs showed significant suppression of the immune-related pathways (Fig. 2b, Supplement Fig. 3, and Supplement Table 5).

Figure 2
Analysis of gene set enrichment for interferon, inflammation, and immune response genes (a) Interferon-related gene sets from GO MSigDB, comparing LSCs and Blasts in AML. (b). Gene set enrichment analysis of combined inflammation and immune gene sets, ...

However, comparison between LSCs (which showed lower expression of TEs than pHSCs) and pHSCs showed no significant differences in interferon, immune, or inflammatory pathways (Supplement Fig. 3). This appeared to contradict the model of TE-induced activation of immune pathways. We therefore investigated alternate pathways that could suppress in immune pathways in pHSCs. Interestingly, we found that all pHSCs exhibited very high expression of EVI-1 (pHSCs vs. LSCs, 4.6-fold, p < 0.0001; pHSCs vs. Blasts, 3.4-fold, p < 0.0001, Supplement Fig. 4), which is known to suppress immune pathways by downregulating NFκB (a pathway known to be activated by viral RNA)23. Consistent with this finding, we also observed that NFκB pathways were more suppressed in pHSCs than Blasts (Blasts and pHSCs showed similar expression of TEs) (Supplemental Fig. 4). These findings suggested that both LSCs and pHSCs showed suppression of NFκB and immune-related pathways, compared to Blasts. LSCs showed suppressed TE expression and pHSCs showed high expression of EVI-1.

Coding gene networks are co-regulated with TEs

Although TE expression is known to activate immune pathways, the types of TEs that participate in this mechanism are currently unknown. In order to understand the relationship between coding gene expression and the expression of specific TE subtypes, we first performed an unsupervised clustering of the AML samples based on coding gene expression, and found that LSCs formed a well-grouped cluster (Fig. 3). We then analysed the corresponding expression of various TE types and observed a significant suppression in the expression of specific TE types such as Alu, ERV3, ERVK, and LTR retrotransposons in LSCs, compared to pHSCs and Blasts (Fig. 3). This suggested that coding gene expression was distinct in samples with low expression of specific types of TEs (LSCs).

Figure 3
Unsupervised hierarchical clustering of coding gene expression in patient samples and the expression levels of the corresponding transposable elements (a) The image on top depicts the hierarchical clustering of each group (pHSC, LSC, and Blast) based ...

Next, in order to investigate which coding gene networks were correlated with specific TE types, we created a genomic association table using the transcriptome from Blasts and LSCs, as shown in Fig. 4. The coding genes were first clustered based on their co-expression to form specific modules. Each module contained unique set of genes that were likely co-regulated and had functional similarities. For example, module 26 contains many RNA helicase genes (Supplement Fig. 5). We correlated these modules to the expression of specific TE types and found that some modules were positively or negatively correlated with the expression of specific TE types. We performed a pathway analysis using the genes in each module for testing the interferon, immune and inflammatory activity, comparing Blasts to LSCs. We identified modules that showed activation (modules 3, 5, 13, 14, 17 and 41) and suppression (22, 24, 26, 29, 30, 39 and 46) of interferon/immune/inflammation gene pathways in Blasts, compared to LSCs (Fig. 4 and Supplement Fig. 5). We then correlated this with the expression of different TE types. As shown in the Fig. 4, the modules that had shown activation of interferon/immune/inflammation genes were positively associated with the expression of specific TE types (Alu, ERVL, ERVK, and LTR retrotransposons) and negatively associated with the expression of ERV1, SAT, and L1. The modules that had shown suppression of the genes in interferon/immune/inflammation were positively associated with the expression of ERV1 and negatively associated with Alu, ERV3, ERVL, and LTR retrotransposons. Chi-square test confirmed a global association between the correlation of positive/negative coding gene module with TE types and the positive/negative enrichment activity of the interferon/immune/inflammation pathways, respectively (p = 0.005). This suggested that specific types of TE were significantly linked to interferon/immune/inflammatory pathway activation.

Figure 4
Identifying significant associations between the expression of coding gene network and the transposable element types in AML. The numbers on the Y-axis denote the gene ‘modules’ constructed by identifying gene networks based on co-expression ...

High-risk cases of MDS show suppression of TEs

In order to validate the observation that TEs induced inflammatory pathway activation in Blasts in an independent model, we analysed the expression of TEs in MDS, comparing CD34 + cells from low-risk and high-risk cases of MDS. MDS cases with refractory anaemia with excess blasts (RAEB) were classified as high-risk and the others were considered low-risk. The two groups were compared using RNA sequencing data from Wang et al.24. We identified significant suppression of TE expression in high-risk MDS, compared to low risk MDS (Fig. 5a). High-risk MDS specifically showed suppression of Type 1 interferon genes, which are known to be activated by viral RNA (Fig. 5b). Inflammation-related genes (Figure 5c, 2-fold change, p = 0.0002, FDR = 0.0003 and Supplement Fig. 6) were also significantly suppressed in high-risk MDS, compared to low risk-MDS. The model validated many of the features of AML development (Fig. 1, Fig. 2), where suppression of TEs is associated with diminished expression of interferon and inflammatory genes.

Figure 5
Expression of transposable elements in myelodysplastic syndrome (MDS) (a) Differential TE expression between low- and high-risk MDS cases. The legends showing TE type and class are identical to Fig. 1A. (b) Expression of type-1 interferon genes ...

To further characterise the association between coding genes and TE expression, we created an association table similar to that for AML shown in Fig. 4 (Fig. 5d). The data indicated a similar association between gene modules (module 3, 4, 5, 9 and 10) that showed activation of immune/inflammatory genes in low-risk MDS compared to high-risk MDS and the expression of specific TE types such as ERV3, ERVL, and LTR retrotransposons. These modules also showed a negative correlation with the expression of ERV1 and L1 (Fig. 5d and Supplement Fig. 7). Type 1 interferon genes were present in only module 9 and 10. These data indicated that similar to LSCs in AML, high-risk cases of MDS exhibited suppressed expression of specific TE types along with the corresponding suppression of interferon and inflammatory pathways.

Pathways that potentially mediate suppression of TEs in LSCs

The mechanisms behind the regulation of TEs have not been thoroughly investigated. Similar to coding genes, TEs can be regulated both transcriptionally and post-transcriptionally. Epigenetic modifications secondary to alterations in ATRX, P53, and SIRT1 and methylation of DNA, have been shown to regulate the expression of TEs2527. We investigated whether TEs were suppressed in LSCs through epigenetic mechanisms by analysing its chromatin accessibility using the data from assay for transposase accessible chromatin with high-throughput sequencing (ATAC-seq) for pHSCs, LSCs, and Blasts from Corces et al.21. ATAC-seq has been used for genome-wide mapping of chromatin accessibility. It uses Tn5 transposase to insert sequencing adapters into accessible regions of the chromatin and then uses the sequence reads mapped to the genome to infer accessible regions. Principle component analysis showed that pHSCs were clustered separately from LSCs and Blasts (Fig. 6a). Contrary to our expectations, LSCs, despite having low expression of TEs, had more nucleosome-free regions than pHSCs (Fig. 6b). We analysed the differential accessibility by comparing the accessibility of LSCs to pHSCs, and found 18,099 regions that were significantly more accessible and 441 regions that were significantly less accessible in LSCs compared to pHSCs (Fig. 6b and Supplement Table 3). Comparison of LSCs to Blasts showed no significant differences in the accessible regions. These findings suggested that the suppression of TEs in LSCs was likely not due to increased heterochromatin.

Figure 6
Chromatin accessibility in pHSCs, LSCs, and Blasts (a) Multi-dimensional scaling plot with two dimensions showing similarity between different ATACseq samples: pHSC (blue), LSC (red), and Blast (black). (b) Depicts the differential accessibility using ...

Because LSCs showed suppressed TE expression despite having more accessible chromatin, we investigated other pathways that could regulate TE expression. A major mechanism for regulating TEs involves their post-transcriptional degradation2830. We analysed genes known to suppress TEs post-transcriptionally, as described by Goodier et al.28, and compared them in LSCs and Blasts and in high-risk and low-risk MDS. High-risk MDS showed significant upregulation of ATG5, KIAA0430, CALCOCO2, ZC3HAV1, HNRNPL, and PABPC1, compared to low-risk cases. LSCs showed significant upregulation of ATG5 and KIAA0430 (Fig. 7a, Supplement Figure 8). High-risk MDS cases also showed significant upregulation of RNA interference genes such as DROSHA, DICER1, and DGCR8, compared to the low-risk cases, but they were not significantly upregulated in LSCs (Fig. 7a). Similar to the piRNA system in males, KIAA0430 or meiosis arrest female protein 1 is known to play a key role in repressing TEs during oogenesis31. However, its role in regulating TEs in somatic cells has not been reported. Autophagy-related 5 (ATG5), which was significantly upregulated in both LSCs and high-risk MDS cases (Supplement figure 8), mediated autophagy by enabling the formation of autophagy vesicles. Autophagy is a process by which various intracellular components are transported to the lysosomes and degraded. A recent study showed that autophagy mediates the degradation of TE post-transcriptionally32. Interestingly, LAMP2 was also upregulated in both LSCs and high-risk MDS cases (Fig. 7b). Recently, it was shown that LAMP2C, a splice isoform of LAMP2, mediated the degradation of RNA via autophagy (RNAutophagy)3335. HSP90AA1 (heat shock protein 90 kDa α [cytosolic], class A member 1) is a pathogen receptor that activates autophagy and thus controls the viral infection36. This protein was also seen upregulated in high-risk MDS cases and LSCs (Fig. 7a and b).

Figure 7
Expression of genes that modulate transposable elements post-transcriptionally (a) Genes that regulate TE post-transcriptionally. Positive fold-change (Y-axis; y > 0) indicates higher expression in high-risk MDS cases and/or LSCs. ...

RNA helicases are known to bind to and degrade TE post-transcriptionally28, 29, 3740. We found significant upregulation of the DExH class of RNA helicases (DHX) in high-risk MDS cases (Fig. 7c and Supplement figure 8). In particular, DHX15 and DHX9 were almost exclusively expressed in high-risk MDS cases and DHX15 was significantly upregulated in LSCs, compared to Blast (Fig. 7c and Supplement figure 8). These results indicated the possibility that several post-transcriptional mechanisms operated for mediating the suppression of TEs in AML and MDS.

Discussion

Our study is the first to comprehensively evaluate the expression of TEs and its association with coding genes in cancer. We demonstrated that the expression of TEs was dysregulated during the development of AML and MDS, with LSCs and high-risk MDS showing significant suppression. It has been shown that the suppression of the viral recognition pathway conferred resistance to chemotherapy; mutations in MAVS and RIG-1, genes in the viral recognition pathway, have been reported in cancer41. We speculated that the expression of TEs could be a potential mechanism for immune-mediated elimination of cancer cells.

Hypomethylating agents have been found to be useful for treating AML and MDS, and recent studies have reported that the activation of TEs with the subsequent immune activation was important for their efficacy against cancers16, 17. Here, we demonstrated that these mechanisms likely operated naturally during cancer development and progression to enable immune-mediated control of AML and MDS. Despite the efficacy of hypomethylating agents against AML and MDS, only a minority (~20%) of patients responded to this therapy42. Among patients who did respond, most eventually developed resistance to therapy with hypomethylating agents. Understanding the regulation of TEs would help us explore predictive factors for hypomethylating treatment and develop novel strategies to prevent relapse in patients treated with hypomethylating agents.

The role of LSCs in the pathogenesis of AML remains controversial. Our results showed that LSCs clearly suppressed the expression of TEs along with distinct coding gene expression. They also showed more suppression of inflammatory pathways, including the NFκB pathway. Since Blasts are short lived, they probably did not evolve mechanisms to escape immune-mediated attacks. We speculate that LSCs are a subset of Blasts with the ability to evade immune recognition.

pHSCs, despite having similar expression levels of TEs as Blasts, also showed suppression of inflammatory pathways that prevent the activation of immune signalling. EVI-1, which is known to suppress NFκB, was uniquely over-expressed in pHSCs, suggesting that there exists distinct genes which suppress the inflammatory pathways in pHSCs. pHSCs carry mutations in genes regulating the epigenetic machinery and have been clearly demonstrated to precede the development of AML43. pHSCs are resistant to chemotherapy and likely function as reservoirs for relapse of leukaemia44, 45. High expression of TEs in pHSCs makes them vulnerable to clearance through the viral-recognition pathway; however, this event likely never occurs because of EVI1-mediated suppression of NFkB, which is downstream to the viral-recognition pathway. High expression of EVI-1 has been shown to be an indicator of poor risk in AML46. Our analysis is the first to highlight that EVI-1 was significantly expressed at high levels in pHSCs. Targeting EVI-1 in pHSCs could help prevent clonal evolution in AML. For example, miR-133 is known to target EVI-147. It would be important to explore its role in clonal haematopoiesis in the elderly, a condition characterized by expansion of haematopoietic stem cells with mutations in pHSCs.

Our analysis that correlated the expression of coding gene networks to the expression of TE types revealed an association between inflammatory pathways to SINE and LTR families and an anti-association with LINE1. Among the types of TEs, LINE1 is known to have the highest activity of retrotranspositioning and thus has the most potential to cause genomic instability. Hence, LSCs might have co-opted to evolve by suppressing the inflammation-inducing TE classes, while retaining the expression of LINE1, which could potentiate genomic instability and hence clonal evolution.

We found high expression of several DExH RNA helicases in high-risk MDS. Recent study by Aktas et al. showed that suppression of DHX9 lead to increased levels of Alu48. DHX9 was one of the RNA helicases upregulated in LSCs anf high-risk MDS in our study. Targeting DHX9 hence could lead to activation of cancer immunogenicity. Importantly, DHX9 is currently being explored as a target for cancer therapy4953. RNA helicases bind to single as well as double stranded RNA, and regulate gene splicing. Aberrant splicing events have been reported in patients with MDS, but it is not known whether these splicing factors also regulate TEs. Exploring this function of RNA helicases would enable us to develop drugs targeting them to activate TEs in AML and MDS. In addition to RNA helicases, the role of autophagy in protecting cancer cells from immune attacks via suppressing TE needs to be explored. Drugs targeting autophagy, RNA autophagy (mediated by LAMP2C) in particular, could be promising therapeutic agents against AML and MDS.

Immuno-oncology is emerging as one of the cornerstones of treatment of various cancers. Interferons have long been used in the treatment of cancers, leading to sustained remissions5456. However, it has been associated with significant systemic toxicities. Activating suppressed TEs, which are known to activate interferons, in cancer cells could potentially accomplish this in a targeted manner.

Our study is the first to show dysregulation of TE in LSCs, revealing its importance in the pathogenesis of AML and MDS. Studying direct mechanisms of the regulation of cancer immunosurveillance by TEs in AML and MDS could lead to therapies improving long-term survival by manipulating the expression of TEs in leukemic cells.

Electronic supplementary material

Acknowledgements

This project was funded by grants from the Leukemia Lymphoma Society-Quest for Cures #0863-15, STOP Cancer, Tower Cancer Research Foundation, and the Keck School of Medicine of the University of Southern California, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California.

Author Contributions

Author Contributions

A.C. wrote the manuscript, analysed the experiments, and developed analytical bioinformatics software and revised the biological model. A.Z. developed the ATACseq software, processed, and analysed the ATACseq experimental data. D.T. revised the theoretical model in regard to the regulation of T.E. elements including key genes relating to autophagy. S.N. provided insight furthering the theoretical framework with regard to the role of helicases in mediating T.E. T.J. developed bioinformatics software. G.R. developed the theoretical model, analysed the experiments and wrote the manuscript.

Notes

Competing Interests

The authors declare that they have no competing interests.

Footnotes

Electronic supplementary material

Supplementary information accompanies this paper at doi:10.1038/s41598-017-07356-9

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Timothy J. Triche, moc.liamg@ehcirt.mit.

Giridharan Ramsingh, ude.csu.dem@hgnismar.

References

1. Belancio VP. LINE-1 activity as molecular basis for genomic instability associated with light exposure at night. Mob Genet. Elements. 2015;5:1–5. doi: 10.1080/2159256X.2015.1037416. [PMC free article] [PubMed] [Cross Ref]
2. Kemp JR, Longworth MS. Crossing the LINE Toward Genomic Instability: LINE-1 Retrotransposition in Cancer. Front. Chem. 2015;3:68. doi: 10.3389/fchem.2015.00068. [PMC free article] [PubMed] [Cross Ref]
3. Mills RE, Bennett EA, Iskow RC, Devine SE. Which transposable elements are active in the human genome? Trends Genet. 2007;23:183–191. doi: 10.1016/j.tig.2007.02.006. [PubMed] [Cross Ref]
4. Luzhna L, Ilnytskyy Y, Kovalchuk O. Mobilization of LINE-1 in irradiated mammary gland tissue may potentially contribute to low dose radiation-induced genomic instability. Genes Cancer. 2015;6:71–81. [PMC free article] [PubMed]
5. Gerdes, P., Richardson, S. R., Mager, D. L. & Faulkner, G. J. Transposable elements in the mammalian embryo: pioneers surviving through stealth and service. Genome Biol. 17, 100-016-0965-5 (2016). [PMC free article] [PubMed]
6. Ge, S. X. Exploratory bioinformatics investigation reveals importance of “junk” DNA in early embryo development. BMC Genomics18, 200-017-3566-0 (2017). [PMC free article] [PubMed]
7. Elbarbary, R. A., Lucas, B. A. & Maquat, L. E. Retrotransposons as regulators of gene expression. Science351, aac7247 (2016). [PMC free article] [PubMed]
8. Sundaram V, et al. Widespread contribution of transposable elements to the innovation of gene regulatory networks. Genome Res. 2014;24:1963–1976. doi: 10.1101/gr.168872.113. [PubMed] [Cross Ref]
9. Thompson PJ, Macfarlan TS, Lorincz MC. Long Terminal Repeats: From Parasitic Elements to Building Blocks of the Transcriptional Regulatory Repertoire. Mol. Cell. 2016;62:766–776. doi: 10.1016/j.molcel.2016.03.029. [PMC free article] [PubMed] [Cross Ref]
10. Lee HE, Ayarpadikannan S, Kim HS. Role of transposable elements in genomic rearrangement, evolution, gene regulation and epigenetics in primates. Genes Genet. Syst. 2015;90:245–257. doi: 10.1266/ggs.15-00016. [PubMed] [Cross Ref]
11. Schulz WA, Steinhoff C, Florl AR. Methylation of endogenous human retroelements in health and disease. Curr. Top. Microbiol. Immunol. 2006;310:211–250. [PubMed]
12. Groh, S. & Schotta, G. Silencing of endogenous retroviruses by heterochromatin. Cell Mol. Life Sci. (2017). [PubMed]
13. Wang J, et al. Inhibition of activated pericentromeric SINE/Alu repeat transcription in senescent human adult stem cells reinstates self-renewal. Cell. Cycle. 2011;10:3016–3030. doi: 10.4161/cc.10.17.17543. [PMC free article] [PubMed] [Cross Ref]
14. Sun D, et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell. Stem Cell. 2014;14:673–688. doi: 10.1016/j.stem.2014.03.002. [PMC free article] [PubMed] [Cross Ref]
15. Mullins CS, Linnebacher M. Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes. Cancer Immunol. Immunother. 2012;61:1093–1100. doi: 10.1007/s00262-011-1183-3. [PubMed] [Cross Ref]
16. Chiappinelli KB, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015;162:974–986. doi: 10.1016/j.cell.2015.07.011. [PMC free article] [PubMed] [Cross Ref]
17. Roulois D, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell. 2015;162:961–973. doi: 10.1016/j.cell.2015.07.056. [PMC free article] [PubMed] [Cross Ref]
18. Lehner B, Williams G, Campbell RD, Sanderson CM. Antisense transcripts in the human genome. Trends Genet. 2002;18:63–65. doi: 10.1016/S0168-9525(02)02598-2. [PubMed] [Cross Ref]
19. Yelin R, et al. Widespread occurrence of antisense transcription in the human genome. Nat. Biotechnol. 2003;21:379–386. doi: 10.1038/nbt808. [PubMed] [Cross Ref]
20. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997;3:730–737. doi: 10.1038/nm0797-730. [PubMed] [Cross Ref]
21. Corces MR, et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 2016;48:1193–1203. doi: 10.1038/ng.3646. [PMC free article] [PubMed] [Cross Ref]
22. Reinisch A, Chan SM, Thomas D, Majeti R. Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Semin. Hematol. 2015;52:150–164. doi: 10.1053/j.seminhematol.2015.03.008. [PMC free article] [PubMed] [Cross Ref]
23. Xu X, et al. EVI1 acts as an inducible negative-feedback regulator of NF-kappaB by inhibiting p65 acetylation. J. Immunol. 2012;188:6371–6380. doi: 10.4049/jimmunol.1103527. [PMC free article] [PubMed] [Cross Ref]
24. Wang H, Wen J, Chang CC, Zhou X. Discovering transcription and splicing networks in myelodysplastic syndromes. PLoS One. 2013;8:e79118. doi: 10.1371/journal.pone.0079118. [PMC free article] [PubMed] [Cross Ref]
25. Leonova KI, et al. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc. Natl. Acad. Sci. USA. 2013;110:E89–98. doi: 10.1073/pnas.1216922110. [PubMed] [Cross Ref]
26. Elsasser SJ, Noh KM, Diaz N, Allis CD, Banaszynski LA. Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells. Nature. 2015;522:240–244. doi: 10.1038/nature14345. [PMC free article] [PubMed] [Cross Ref]
27. Van Meter M, et al. SIRT6 represses LINE1 retrotransposons by ribosylating KAP1 but this repression fails with stress and age. Nat. Commun. 2014;5:5011. doi: 10.1038/ncomms6011. [PMC free article] [PubMed] [Cross Ref]
28. Goodier, J. L. Restricting retrotransposons: a review. Mob DNA7, 16-016-0070-z. eCollection 2016 (2016). [PMC free article] [PubMed]
29. Goodier JL, Cheung LE, Kazazian HH., Jr. MOV10 RNA helicase is a potent inhibitor of retrotransposition in cells. PLoS Genet. 2012;8:e1002941. doi: 10.1371/journal.pgen.1002941. [PMC free article] [PubMed] [Cross Ref]
30. Goodier JL, Cheung LE, Kazazian HH., Jr. Mapping the LINE1 ORF1 protein interactome reveals associated inhibitors of human retrotransposition. Nucleic Acids Res. 2013;41:7401–7419. doi: 10.1093/nar/gkt512. [PMC free article] [PubMed] [Cross Ref]
31. Su YQ, Sun F, Handel MA, Schimenti JC, Eppig JJ. Meiosis arrest female 1 (MARF1) has nuage-like function in mammalian oocytes. Proc. Natl. Acad. Sci. USA. 2012;109:18653–18660. doi: 10.1073/pnas.1216904109. [PubMed] [Cross Ref]
32. Guo H, et al. Autophagy supports genomic stability by degrading retrotransposon RNA. Nat. Commun. 2014;5:5276. doi: 10.1038/ncomms6276. [PubMed] [Cross Ref]
33. Fujiwara Y, et al. Discovery of a novel type of autophagy targeting RNA. Autophagy. 2013;9:403–409. doi: 10.4161/auto.23002. [PMC free article] [PubMed] [Cross Ref]
34. Fujiwara Y, Hase K, Wada K, Kabuta T. An RNautophagy/DNautophagy receptor, LAMP2C, possesses an arginine-rich motif that mediates RNA/DNA-binding. Biochem. Biophys. Res. Commun. 2015;460:281–286. doi: 10.1016/j.bbrc.2015.03.025. [PubMed] [Cross Ref]
35. Hase K, et al. RNautophagy/DNautophagy possesses selectivity for RNA/DNA substrates. Nucleic Acids Res. 2015;43:6439–6449. doi: 10.1093/nar/gkv579. [PMC free article] [PubMed] [Cross Ref]
36. Hu B, et al. Binding of the pathogen receptor HSP90AA1 to avibirnavirus VP2 induces autophagy by inactivating the AKT-MTOR pathway. Autophagy. 2015;11:503–515. doi: 10.1080/15548627.2015.1017184. [PMC free article] [PubMed] [Cross Ref]
37. Bryk M, Banerjee M, Conte D, Jr, Curcio MJ. The Sgs1 helicase of Saccharomyces cerevisiae inhibits retrotransposition of Ty1 multimeric arrays. Mol. Cell. Biol. 2001;21:5374–5388. doi: 10.1128/MCB.21.16.5374-5388.2001. [PMC free article] [PubMed] [Cross Ref]
38. Ott KM, Nguyen T, Navarro C. The DExH box helicase domain of spindle-E is necessary for retrotransposon silencing and axial patterning during Drosophila oogenesis. G3 (Bethesda) 2014;4:2247–2257. doi: 10.1534/g3.114.014332. [PMC free article] [PubMed] [Cross Ref]
39. Taylor MS, et al. Affinity proteomics reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. Cell. 2013;155:1034–1048. doi: 10.1016/j.cell.2013.10.021. [PMC free article] [PubMed] [Cross Ref]
40. Wu-Scharf D, Jeong B, Zhang C, Cerutti H. Transgene and transposon silencing in Chlamydomonas reinhardtii by a DEAH-box RNA helicase. Science. 2000;290:1159–1162. doi: 10.1126/science.290.5494.1159. [PubMed] [Cross Ref]
41. Ranoa DR, et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget. 2016;7:26496–26515. doi: 10.18632/oncotarget.8420. [PMC free article] [PubMed] [Cross Ref]
42. Yun, S. et al. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clin. Epigenetics8, 68-016-0233-2. eCollection 2016 (2016). [PMC free article] [PubMed]
43. Jan M, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 2012;4:149ra118. doi: 10.1126/scitranslmed.3004315. [PMC free article] [PubMed] [Cross Ref]
44. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. USA. 2014;111:2548–2553. doi: 10.1073/pnas.1324297111. [PubMed] [Cross Ref]
45. Corces-Zimmerman MR, Majeti R. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia. 2014;28:2276–2282. doi: 10.1038/leu.2014.211. [PMC free article] [PubMed] [Cross Ref]
46. Haas K, et al. Expression and prognostic significance of different mRNA 5’-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer. 2008;47:288–298. doi: 10.1002/gcc.20532. [PubMed] [Cross Ref]
47. Yamamoto H, et al. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target. Sci. Rep. 2016;6:19204. doi: 10.1038/srep19204. [PMC free article] [PubMed] [Cross Ref]
48. Aktas T, et al. DHX9 suppresses RNA processing defects originating from the Alu invasion of the human genome. Nature. 2017;544:115–119. doi: 10.1038/nature21715. [PubMed] [Cross Ref]
49. Lee T, et al. Suppression of the DHX9 helicase induces premature senescence in human diploid fibroblasts in a p53-dependent manner. J. Biol. Chem. 2014;289:22798–22814. doi: 10.1074/jbc.M114.568535. [PMC free article] [PubMed] [Cross Ref]
50. Lee T, Pelletier J. The biology of DHX9 and its potential as a therapeutic target. Oncotarget. 2016;7:42716–42739. doi: 10.18632/oncotarget.8446. [PMC free article] [PubMed] [Cross Ref]
51. Cencic R, Senechal P, Pelletier J. Establishment of a Primary Screening Assay for the DHX9 Helicase. Comb. Chem. High Throughput Screen. 2015;18:855–861. doi: 10.2174/1386207318666151019093433. [PubMed] [Cross Ref]
52. Mills JR, et al. RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Emu-myc/Bcl-2 mouse model. Blood. 2013;121:3402–3412. doi: 10.1182/blood-2012-06-434365. [PubMed] [Cross Ref]
53. Lee T, Paquet M, Larsson O, Pelletier J. Tumor cell survival dependence on the DHX9 DExH-box helicase. Oncogene. 2016;35:5093–5105. doi: 10.1038/onc.2016.52. [PMC free article] [PubMed] [Cross Ref]
54. Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia. 2013;27:803–812. doi: 10.1038/leu.2012.313. [PMC free article] [PubMed] [Cross Ref]
55. Ortiz A, Fuchs SY. Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine. 2017;89:4–11. doi: 10.1016/j.cyto.2016.01.010. [PMC free article] [PubMed] [Cross Ref]
56. Hasselbalch HC. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev. Hematol. 2011;4:637–655. doi: 10.1586/ehm.11.63. [PubMed] [Cross Ref]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group